Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
Presentations on tau to explore its biological role, the development of targeted therapies and biomarkers, and the future integration of these innovations into clinical practice
CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer's Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau.
'At AAIC, we are sharing data that underscore our ongoing efforts to advance both how Alzheimer's is treated and how care is delivered, including 48-month findings from the LEQEMBI Clarity AD open-label extension and new insights into the potential of subcutaneous maintenance dosing for LEQEMBI. We are also excited to share baseline characteristics from CELIA, our Phase 2 study of BIIB080, an investigational ASO therapy targeting tau,' said Priya Singhal, M.D., M.P.H., Head of Development at Biogen. 'As we deepen our understanding of this complex disease, we remain committed to pushing the science forward and evolving care to better meet the needs of patients and families.'
Key Scientific Sessions and Presentations:
Lecanemab Clarity AD OLE in Early AD: Initial Findings from 48-Month AnalysisWednesday, July 30, 8:00–8:45 AM ET
Lecanemab Subcutaneous Formulation for Maintenance Dosing: The Potential of a New and Convenient Option for Ongoing Treatment in Early Alzheimer's DiseaseWednesday, July 30, 9:00–10:30 AM ET
Patient, Care Partner, and Health Care Professional Opinion of the Lecanemab Autoinjector for Subcutaneous DeliverySunday, July 27, 8:00–8:45 AM ET
Lecanemab Two Years Post-Approval: Real-World Case Series and Patient Pathway LearningsSunday, July 27, 9:00–10:30 AM ET
Indirect Treatment Comparison of ARIA Outcomes for Lecanemab Compared to Donanemab Based on Reported ResultsSunday, July 27, 4:14–5:45 PM ET
Innovations in Tau Therapies and Biomarkers for Alzheimer's Disease: Bridging Research and Clinical PracticeWednesday, July 30, 2:00–3:30 PM ET
Baseline Characteristics from CELIA: A Phase 2 Study to Evaluate BIIB080 in Participants with Early Alzheimer's DiseaseMonday, July 28, 7:30 AM–4:15 PM ET
Educational Program on Tau in Alzheimer's Disease At AAIC, Biogen will host an interactive booth offering an immersive journey into the role of tau in Alzheimer's disease, from pathology to clinical presentation. Biogen is also expanding its educational efforts with a new e-learning module on KnowTau.com, building on the resources already available.
For more information, please see the AAIC 2025 program and visit the Biogen AAIC booth.
About BIIB080BIIB080 is an investigational antisense oligonucleotide (ASO) therapy designed to target microtubule-associated protein tau (MAPT) mRNA to reduce the production of tau protein. Abnormal accumulation of tau in the brain is a hallmark of Alzheimer's disease and is associated with neurodegeneration and cognitive decline. BIIB080 is currently being evaluated in a Phase 2 clinical study (NCT05399888) in individuals with early Alzheimer's disease.
In December 2019, Biogen exercised a license option with Ionis Pharmaceuticals and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB080 (tau ASO). BIIB080 was discovered by Ionis.
About LEQEMBI ® (lecanemab)LEQEMBI (lecanemab) is the result of a strategic research alliance between Eisai and BioArctic. LEQEMBI is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). LEQEMBI is an amyloid beta-directed antibody for the treatment for Alzheimer's disease (AD) in the U.S. The U.S. Food and Drug Administration (FDA) granted LEQEMBI traditional approval on July 6, 2023.
LEQEMBI is indicated for the treatment of Alzheimer's disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.
Please see full U.S. Prescribing Information for LEQEMBI, including Boxed WARNING and Medication Guide.
About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, LinkedIn, X, YouTube.
Biogen Safe Harbor This news release contains forward-looking statements, including about the potential clinical effects of lecanemab and BIIB080; the potential benefits, safety and efficacy of lecanemab and BIIB080; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer's disease; the anticipated risks, benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab and BIIB080; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as 'aim,' 'anticipate,' 'assume,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'guidance,' 'hope,' 'intend,' 'may,' 'objective,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'prospect,' 'should,' 'target,' 'will,' 'would,' and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.
These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; risks associated with third party collaborations; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; risks of unexpected costs or delays or other unforeseen hurdles; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission.
These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned 'Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.
MEDIA CONTACT:BiogenMadeleine Shin+ 1 781 464 3260public.affairs@biogen.com
INVESTOR CONTACT:BiogenTim Power+1 781 464 2442IR@biogen.com Error al recuperar los datos
Inicia sesión para acceder a tu cartera de valores
Error al recuperar los datos
Error al recuperar los datos
Error al recuperar los datos
Error al recuperar los datos
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
18 minutes ago
- Gizmodo
Gluten Could Be Wrongly Blamed for Americans' Stomach Troubles
For many of us, gluten is a dietary villain, capable of causing all sorts of gastrointestinal troubles. Research out this week looks to complicate that narrative, however, finding that people are sometimes wrongly blaming gluten for triggering their symptoms of irritable bowel syndrome. Scientists at McMaster University in Canada conducted the study, a small, randomized trial of IBS patients. People became sicker just as often after eating food containing gluten or wheat as they did after eating food without the ingredient, they found. Gluten is likely safer to eat for those with IBS than commonly thought, the researchers say. 'These findings suggest that expectations played a major role in symptom generation and that only some of these patients could benefit from gluten or wheat restriction,' they wrote in their paper, published Monday in The Lancet Gastroenetrology and Hepatology. IBS is a complex, chronic, and relatively common condition, estimated to affect between 5 and 10% of the population worldwide (including up to 45 million people in the U.S.). Its symptoms include stomach pain, bloating, and diarrhea or constipation. Unlike the closely named inflammatory bowel disorder, IBS isn't marked by physical changes or visible damage along the digestive tract, but it can still be a debilitating burden for many, with around 20% of sufferers experiencing severe bouts. The exact causes of IBS remain unclear, though scientists have speculated it can arise from a miscommunication between the nerves found in the gut and the brain. People with IBS tend to report having specific triggers that can cause a flare-up of illness, gluten included, and often manage their condition by avoiding these triggers. The researchers behind the new study aimed to better understand gluten's potential role in IBS, so they recruited over two dozen people with IBS for their randomized, double-blinded trial, all of whom had reported improving after switching to a gluten-free diet. At first, the volunteers were randomly assigned to one of three groups. All the groups were first told to eat cereal bars for a week. One group ate bars made with flour containing gluten, the second ate bars made with wheat flour, and the third ate bars made with gluten- and wheat-free flour. Afterward, the volunteers took a break for two weeks. Then they switched to eating the bars they hadn't eaten yet for another round of testing, a process repeated twice. By the study's end, all the volunteers had eaten all three kinds of bars, though on different schedules and without knowing which bars they had eaten on a given week. A total of 28 people completed the trial. A significant percentage of people reported having worsening IBS symptoms after eating gluten or wheat bars, the study showed, but about just as often as they did after eating non-gluten/wheat bars (roughly a third experienced worsening IBS during each of the three conditions). 93% of participants also reported having adverse events after each scenario of bar-eating. Interestingly enough, tests of the participants' stool found that only a third strictly followed their diets as instructed, with likely many fearing they would get sick. The findings are based on a very small sample size, so it's not yet certain that they apply to the general population of people with IBS tied to gluten. There are also, of course, digestive conditions clearly caused by an intolerance to gluten, particularly celiac disease. And the researchers aren't saying gluten can't sometimes be a genuine trigger for people's IBS. But they argue that in many cases, people's negative perception of gluten is causing a nocebo effect, the dark cousin of the placebo effect. In other words, someone's belief that gluten is bad for them can potentially spark or worsen the IBS symptoms seen after eating it, rather than gluten itself. The researchers say better communication and follow-up care from doctors are needed for IBS patients, given the findings. 'What we need to improve in our clinical management of these patients is to work with them further, not just tell them that gluten is not the trigger and move on. Many of them may benefit from psychological support and guidance to help destigmatize gluten and wheat and reintroduce them safely in their diet,' said senior author Premysl Bercik, a professor at McMaster's Department of Medicine, in a statement from the university. That may be easier said than done, though. The researchers note that most patients, upon learning the team's findings, staunchly refused to entertain the idea of gluten not being a trigger for their IBS symptoms. So it looks like gluten may need a promotional campaign to win back its reputation.
CNET
an hour ago
- CNET
We're Surviving This Summer's Heat Wave With These Must-Have Cooling Products
Hot weather is here, and this week's heat wave has been stifling. It's important to stay safe when having fun in the sun this summer. So, if you plan to spend time outside, be sure you're prepared with the essentials to keep cool. Here are 10 items you can use to survive this year's heat waves and summer highs. 1. Cooling towels A handheld towel is excellent for drying off after exercising, playing sports or doing hard work under the sun. A cooling towel is a step above. Just get these towels wet with cold water and wring out the extra water. Then, wrap the cooling towel around your neck or dab your face; it should stay cool for up to 2 hours. When it starts to warm up again, just add more water and repeat the process. These towels are great for a hot, summertime walk, relaxing at the beach or a long hike up the mountains. Mission Mission Cool Anywhere Towels These reusable, two-pack microfiber towels come in two different colors. They also offer UPF 50 sun protection. $20 at Amazon 2. Electrolyte powder When you spend lots of time in the heat, your body actively loses water and electrolytes -- minerals found in the body that have a charge -- through sweat. It's important to replace that lost water and electrolytes with fluids. If you struggle to drink eight cups of water a day in the summer (and sometimes you need more if you're extremely active in the heat), an electrolyte drink can help replenish your body. The best electrolyte powders usually contain sodium, calcium, potassium, phosphate, chloride or magnesium. Electrolytes such as these can balance your body's water and pH levels, move nutrients throughout your cells, carry out waste from your cells, and ensure all muscles, bodily functions and nerves are working correctly. Amazon/Screenshot by CNET Liquid I.V. Hydration Multiplier Liquid I.V. powder provides two times faster hydration than water alone. It includes five vitamins and and many electrolytes. One bag of Liquid I.V. includes 16 on-the-go packets. Add one packet to 16 ounces of water and stir. $23 at Amazon 3. Reusable water bottle Rule No. 1 for surviving the heat: drink lots of water. Whether this is water or an electrolyte drink, hydration in the summer is key. You don't want to become dehydrated. Dehydration symptoms include tired, dark yellow urine, sunken eyes, headache and lightheadedness. I find that I drink the most water when I carry a water bottle around with me. I also drink more water when it stays ice cold throughout the day. An insulated stainless steel water bottle will do just that. Amazon/Screenshot by CNET Hydro Flask Choose between an 18-, 21- or 24-ounce Hydro Flask. Made with Pro-Made stainless steel, this water bottle is non-free, BPA-free and keeps water cold for up to 24 hours. $32 at Amazon 4. Portable fan A portable fan is handy when you miss the indoors or are dealing with broken AC. Cool down while walking, traveling or doing anything in the sun. It can even be useful for summer camping or hanging at the beach. Look for a portable fan that is easily rechargeable. Some fans can even mist your face. Amazon/Screenshot by CNET JISULIFE Handheld Mini Fan This chargeable, handheld fan is also a flashlight and a portable charger. Speed one can last up to 21 hours between charging and speed two can last up to 14 hours. $18 at Amazon 5. Sunscreen If you want to beat the heat, you first need to make sure your skin is protected. Wearing sunscreen should always be a priority if you're doing anything outside this summer. In addition to wearing sunglasses, a hat or UV protective clothing, sunscreen provides a shield to your delicate skin. Sunscreen provides protection from sun cancer, signs of sun damage and premature aging. You can try chemical, mineral or combo sunscreen. If you want a sunscreen that won't leave a white cast, look for a product with a light serum. If you have acne-prone skin, use a sensitive mineral or combo sunscreen. Amazon/Screenshot by CNET Neutrogena Mineral UltraSheer Dry-Touch Sunscreen Neutrogena Mineral UltraSheer Dry-Touch is lightweight, clean and contains SPF 30. It is water-resistant for up to 80 minutes. $9 at Amazon 6. Countertop ice machine There is nothing better than an ice-cold drink on a hot day. A countertop ice machine can bring the ice directly to you. You can add ice to your water or store beverages and take them with you; a countertop ice machine can be transported from one place to another. Take it camping orbring it to an outdoor party. You can have cold ice handy as long as you have access to an outlet. Amazon/Screenshot by CNET Igloo Portable Electric Countertop Ice Maker This Igloo ice maker can make ice in two different sizes. Just add water, select your ice size and ice will be ready in 7 minutes. There are multiple self-cleaning settings. $95 at Amazon 7. Cooling pillow When sleeping cool, using a fan, AC or light pajamas might be your go-to solution. However, changing your bedding is another easy fix. A cooling pillow is designed not to retain any body heat and to provide as much breathability as possible. Some cooling pillows even have a cool-to-the-touch cover. Pillows made of materials such as non-perforated and non-gel memory foam trap heat and will only make you hotter at night. Look for cooling pillows made of latex, foam, silk, cotton or bamboo. Note that the pillowcase you use may affect the cooling sensation of any pillow. I recommend looking for a silk, satin or light cotton pillowcase to accompany your cooling pillow. 8. Neck fan Why hold a fan in front of your face when one can sit on your neck? If you're working outside or have your hands full, a neck fan is practical. Shaped like headphones, neck fans wrap around the neck and both sides blow up toward the sides of your face and back of your neck. It's perfect for sitting inside without AC or working under the sun. Amazon/Screenshot by CNET ASNUG Neck Fan The ASNUG Neck Fan is blade-less, meaning that it won't snag hair, fingers or clothing. It has three settings and is rechargable via USB. $27 at Amazon 9. Cooling sheets Similar to cooling pillows, cooling sheets can help dissipate your body heat. Cooling sheets are never made with materials like flannel or heavy cotton that trap heat. The best sheets for the summer will be made with bamboo, cotton, silk, Tencel, linen, polyester, microfiber or lyocell. For optimal summer bedding, switch to cooling sheets, a cooling comforter, a cooling pillowcase and a cooling pillow. Amazon/Screenshot by CNET Sheets & Giggles Sheet Set These temperture-balancing, lyocell sheets come in Twin, Twin XL, Full, Queen, King, California King and Split King sizes. Each set includes one flat sheet, one fitted sheet and two pillowcases. $190 at Amazon 10. Cold facial mask A fun way to cool down is to use a cold facial mask. While I don't recommend wearing this outside, a cold compress can help calm hot, sweaty skin and bring down your internal temperature after being outside in the sun. Similar to cold rollers or certain eye creams, a cold face mask can even help depuff eyes. And if you are prone to migraines, a cold facial mask can aid a pounding headache.
Forbes
an hour ago
- Forbes
How President Kennedy's Vision Drove Apollo 11's Triumph
Nations, and organizations, can accomplish great things when guided by clarity of purpose. On July 24, the country celebrates the successful conclusion of the Apollo 11 lunar mission; perhaps the most significant technological triumph in American history. You don't need to be a senior citizen to recognize its relevance. The Apollo 11 triumph reflects the exceptional contributions of a disparate group of scientists, engineers, technicians, astronauts and test pilots. But it was very much born of the bold, clear vision of a young president, and of the extraordinary national commitment that vision generated. And there's a lesson in that for today's organizational leaders. Early in the John F. Kennedy presidency, the country's global prestige had been buffeted by the unanticipated achievements of the Soviet space program, which far outpaced similar efforts of the United States. Soviet spacecrafts were orbiting the earth while American rockets were exploding on the launch pad. The 'space gap' became an unexpected yet powerful weapon in the Cold War. In turn, President Kennedy viewed national leadership in space as critical to preserving the country's world leadership position. This, he felt, could be achieved by pursuing aggressive goals for space exploration. To that end, in a bold address to a joint session of Congress on May 25, 1961, he called for a national commitment 'to achieving the goal, before this decade is out, of landing a man on the moon and returning him safely to the earth.' (Note Kennedy's reference to both 'landing' and 'returning'). In this call before Congress, he pulled no punches, articulating both the promise and the 'heavy burden' associated with his challenge. No single space project in this period will be more impressive to mankind, or more important for the long-range exploration of space; and none will be so difficult or expensive to accomplish. Nations, and organizations, can accomplish great things when guided by clarity of purpose. Kennedy further galvanized public support for this vision with his famous September 12, 1962 speech at Rice University in Houston: We choose to go to the Moon. We choose to go to the Moon in this decade and do the other things, not because they are easy, but because they are hard, because that goal will serve to organize and measure the best of our energies and skills, because that challenge is one that we are willing to accept, one we are unwilling to postpone, and one which we intend to win, and the others, too. Of course, Kennedy did not live to see the success of Apollo 11. Yet his simple, clear and stirring vision for the nation was strong enough to sustain the public commitment and support the scientific effort through the challenges and tragedies of the intervening years. To address the continuing technical barriers of space flight. To confront the loss of confidence from a great tragedy ‒ the Apollo 1 fire. To overcome the significant distractions of an unpopular foreign war and growing national racial strife. Indeed, Apollo 11 returned safely to earth on July 24, 1969; 'in this decade', just as Kennedy had called for. Simply amazing. All of this is a reminder that words do indeed matter. That a thoughtful purpose can breed meaningful commitment. And that a clearly articulated vision can motivate an organization, just as a nation, to pursue and achieve noble goals. With that, the elements of vision-making become more apparent: it's the ability of leadership to succinctly express where the organization needs to go in the future, the reasons why it needs to go in that direction, how it expects to reach the specific destination, the plan for the organization when it gets there, and why the effort will ultimately be worth it. Easier said than done, of course. But President Kennedy's skill in formulating, presenting and advocating for his space exploration goals made it easier for the public to understand and support them. More broadly, it helped them become more acquainted with the young president, and the principles for which he stood. That's the force of an effective vision; a force should be attractive to all leaders ‒ no matter the industry sector.
